Hydroxyzine is the Better Choice for Anxiety and Sleep
For treating both anxiety and sleep disturbances, hydroxyzine is the more appropriate first-line option compared to amitriptyline, based on its FDA-approved indication for anxiety, established efficacy in generalized anxiety disorder, and favorable safety profile for short-term use.
Rationale for Hydroxyzine
FDA-Approved Indication
Hydroxyzine is FDA-approved specifically for "symptomatic relief of anxiety and tension associated with psychoneurosis" 1, making it a legitimate first-line option for anxiety treatment. The FDA label explicitly recognizes its role as a sedative 1, addressing both components of your question.
Evidence for Anxiety
Multiple randomized controlled trials demonstrate hydroxyzine's efficacy in generalized anxiety disorder (GAD):
- A 4-week double-blind study showed hydroxyzine 50 mg/day produced statistically significant anxiolytic effects beginning in the first week, with benefits maintained throughout treatment and after discontinuation without rebound anxiety or withdrawal symptoms 2
- A 3-month trial confirmed sustained efficacy comparable to bromazepam (a benzodiazepine), with hydroxyzine showing superiority over placebo on multiple anxiety measures 3
- A Cochrane systematic review concluded hydroxyzine is more effective than placebo for GAD (OR 0.30,95% CI 0.15 to 0.58) 4
Evidence for Sleep
A 2023 systematic review specifically examining hydroxyzine for insomnia found mixed but positive efficacy for sleep onset, sleep maintenance, and sleep quality across multiple trials 5. The most common side effect—drowsiness—actually becomes therapeutic in this context 2.
Why Not Amitriptyline as First-Line
Lack of Guideline Support
The 2016 American College of Physicians guideline on insomnia found insufficient or low-strength evidence for antidepressants (including amitriptyline) for treating insomnia disorder 6. The guideline explicitly noted that evidence for antidepressants was inadequate compared to other agents.
Off-Label Use with Limited Data
While a 2023 study showed that low-dose amitriptyline (10-20 mg) improved sleep maintenance in 73.9% of patients with insomnia disorder 7, this remains off-label use. The study acknowledged that randomized controlled trials are still needed to establish effectiveness and safety 7.
Anxiety Treatment Not Established
For anxiety specifically, amitriptyline lacks robust modern evidence. A 1976 open-label study showed benefit 8, but this is outdated and methodologically weak. When compared to SSRIs for anxious depression, amitriptyline showed comparable efficacy but significantly worse tolerability 9.
Safety Concerns
Amitriptyline carries substantial anticholinergic burden and cardiovascular risks, particularly problematic in elderly patients or those with cardiac conditions—populations where both anxiety and insomnia are common.
Clinical Algorithm
Start with hydroxyzine 25-50 mg at bedtime for patients presenting with both anxiety and sleep complaints:
- Week 1-4: Assess response. Most patients show improvement within the first week 2
- Tolerability: Expect transient drowsiness that typically diminishes over time 2. Monitor for dry mouth (14% incidence) 2
- Duration: FDA label notes that effectiveness beyond 4 months has not been systematically assessed 1, so plan for short-term use with reassessment
Important Caveats:
- QT prolongation risk: Use caution in patients with cardiac risk factors, concomitant QT-prolonging medications, or electrolyte abnormalities 1
- Elderly patients: Start at lower doses due to increased sensitivity and risk of confusion 1
- Avoid alcohol and CNS depressants: Hydroxyzine potentiates their effects 1
Consider amitriptyline only if:
- Hydroxyzine fails or is contraindicated
- Patient has comorbid chronic pain or neuropathy (where amitriptyline has additional benefits)
- Sleep maintenance is the predominant problem with minimal daytime anxiety
Bottom Line
Hydroxyzine offers FDA-approved anxiolytic effects with sedative properties that address both presenting complaints, supported by multiple RCTs showing efficacy in GAD and emerging evidence for insomnia. Amitriptyline lacks guideline support for insomnia, has weaker anxiety evidence, and carries greater safety concerns. Hydroxyzine should be your first choice, with amitriptyline reserved as a second-line alternative.